

Supplementary Table 1: Clinicopathological characteristics of UC cases

Characteristic		Normal (n=41)	Acute phase (n=40)	Remission phase		CAN	
				MES0 (n=39)	MES1-2 (n=34)	High-grade dysplasia (n=13)	Cancer (n=13)
Gender	Male	22	28	18	20	6	7
	Female	19	11	21	14	7	6
Age at diagnosis, y (median, range)		—	38 (13-80)	36 (5-62)	34 (13-67)	30 (13-65)	24 (9-77)
Age at operation or biopsy , y (median, range)		70 (44-90)	72 (44-90)	52 (18-78)	34 (13-67)	50 (32-81)	53 (27-88)
Disease duration, y (median, range)		—	4 (0-25)	16 (3-35)	8 (0-40)	18 (8-28)	17 (1-36)
Extent of disease	Left side	—	0	1	8	0	1
	Total	—	40	38	17	12	11
	Others	—	0	0	9	1	1


CAN: Colitis-associated neoplasm, MES: Mayo endoscopic score

Supplementary Table 2: Primer sequences for PCR

Primers for RNA editing site-specific quantitative PCR	
Gene	Primer sequence
Wild-type AZIN1	Forward: CATTGAGCTCAGGAAGAAGACATCT
	Reverse: AATACAAGGAAGATGAGCCTCTGTTTAC
Edited AZIN1	Forward: ACTGAATGACATCATGTAATAAATGGCT
	Reverse: GAGCTTGATCAAATTGTGGCAG
Primers for qRT-PCR	
Gene	Primer sequence
ADAR1 (human)	Forward: CCCTTCAGCCACATCCTTC
	Reverse: GCCATCTGCTTTGCCACTT
IFNβ (human)	Forward: GCCATCAGTCACTTAAACAGC
	Reverse: GAAACTGAAGATCTCCTAGCCT
GAPDH (human)	Forward: CTGCACCACCAACTGCTTAG
	Reverse: GTCTTCTGGGTGGCAGTGAT

Obtained from IDT (Coralville, IA, USA).

Supplementary Figure 1: Immunohistochemical staining scoring of ADAR1



ADAR1 staining intensity was evaluated in the nucleus and cytoplasm, respectively. ADAR1 staining score was evaluated for nucleus and cytoplasm separately with our scoring system, measured three times by three independent investigators blinded to the nature of the specimens.